Medline (MDLN) Common Equity (2024 - 2026)

Medline (MDLN) has 3 years of Common Equity data on file, last reported at $19.3 billion in Q1 2026.

• Quarterly Common Equity changed N/A year-over-year to $19.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.3 billion (changed N/A YoY) and the FY2025 annual result came in at $10.7 billion, down 33.55% from the prior year.
• Common Equity grew to $19.3 billion in Q1 2026 per MDLN's latest filing, from $10.7 billion in the prior quarter.
• Across five years, Common Equity topped out at $19.3 billion in Q1 2026 and bottomed at $10.7 billion in Q4 2025.
• The 3-year median for Common Equity is $16.2 billion (2024), against an average of $15.4 billion.
• Peak annual rise in Common Equity reached 33.55% in 2025, while the deepest fall reached 33.55% in 2025.
• Tracing MDLN's Common Equity over 3 years: stood at $16.2 billion in 2024, then plunged by 33.55% to $10.7 billion in 2025, then soared by 80.21% to $19.3 billion in 2026.
• Per Business Quant, the three latest MDLN Common Equity figures stand at $19.3 billion (Q1 2026), $10.7 billion (Q4 2025), and $16.2 billion (Q4 2024).

Peer Comparison